Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26912865 | 1.00 | KDM5B (0.32) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL26912365 | 1.00 | KDM5B (0.32) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL30684276 | 1.00 | KDM5B (0.32) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL26912631 | 0.97 | KDM5B (0.33) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL26913573 | 0.94 | MCL1 (0.31) | KDM5BFGFR1 | |
| SCHEMBL30684197 | 0.92 | KDM5B (0.33) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL26913324 | 0.92 | KDM5B (0.33) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL30684321 | 0.92 | KDM5B (0.33) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL26912583 | 0.92 | KDM5B (0.33) | KDM5BFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL30684326 | 0.92 | JAK3 (0.32) | KDM5BFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | KDM5B 3889/4885FGFR1 2285/4885FGFR2 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.